Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014

Wed Jan 22, 2014 8:30am EST

* Reuters is not responsible for the content in this press release.

Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 30, 2014 at 9 a.m. ET to discuss the fourth quarter and full year 2013 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, PhD
Executive Vice President and Chief Financial Officer
908-673-9956
or
Celgene Corporation
Patrick E. Flanigan III
Vice President
Investor Relations
908-673-9969

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.